Overview

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University